These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38101905)

  • 1. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes.
    Farina A; Villagrán-García M; Vogrig A; Zekeridou A; Muñiz-Castrillo S; Velasco R; Guidon AC; Joubert B; Honnorat J
    Lancet Neurol; 2024 Jan; 23(1):81-94. PubMed ID: 38101905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
    Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
    Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraneoplastic Neurologic Disorders.
    Zekeridou A
    Continuum (Minneap Minn); 2024 Aug; 30(4):1021-1051. PubMed ID: 39088287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis, diagnosis and treatment of paraneoplastic neurologic syndromes.
    Blaes F
    Expert Rev Neurother; 2021 Jun; 21(6):675-686. PubMed ID: 33960258
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-Hu-associated paraneoplastic syndromes triggered by immune-checkpoint inhibitor treatment.
    Mongay-Ochoa N; Vogrig A; Muñiz-Castrillo S; Honnorat J
    J Neurol; 2020 Jul; 267(7):2154-2156. PubMed ID: 32451614
    [No Abstract]   [Full Text] [Related]  

  • 6. Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy.
    Valencia-Sanchez C; Zekeridou A
    Front Neurol; 2021; 12():642800. PubMed ID: 33897597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paraneoplastic Encephalitis and Enteric Neuropathy Associated With Anti-Hu Antibody in a Patient Following Immune-checkpoint Inhibitor Therapy.
    Kang K; Zheng K; Zhang Y
    J Immunother; 2020 Jun; 43(5):165-168. PubMed ID: 32195750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab-induced cerebellar ataxia in a patient with metastatic small cell lung cancer: A case report and literature review.
    Kapagan T; Aksu F; Yuzkan S; Bulut N; Erdem GU
    J Oncol Pharm Pract; 2024 Jan; 30(1):201-205. PubMed ID: 37321205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paraneoplastic neurological syndromes in patients affected by SCLC: a case series.
    Zanella C; Leone AG; Zambelli L; Bottiglieri A; Canziani L; Brambilla M; Lo Russo G; Platania M; De Braud F; Occhipinti M
    Tumori; 2022 Dec; 108(6):NP11-NP14. PubMed ID: 35260015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New concepts in paraneoplastic neurological syndromes.
    Honnorat J; Viaccoz A
    Rev Neurol (Paris); 2011 Oct; 167(10):729-36. PubMed ID: 21890156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity.
    Farina A; Birzu C; Elsensohn MH; Picca A; Muñiz-Castrillo S; Vogrig A; Villagrán-García M; Ciano-Petersen NL; Massacesi L; Hervier B; Guégan S; Kramkimel N; Vano Y; Salem JE; Allenbach Y; Maisonobe T; Assaad S; Maureille A; Devic P; Weiss N; Pegat A; Maucort-Boulch D; Ricard D; Honnorat J; Psimaras D; Joubert B
    Brain Commun; 2023; 5(3):fcad169. PubMed ID: 37389303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paraneoplastic neurological syndromes: clinical presentations and management.
    Devine MF; Kothapalli N; Elkhooly M; Dubey D
    Ther Adv Neurol Disord; 2021; 14():1756286420985323. PubMed ID: 33796141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors.
    Duong SL; Prüss H
    Neurotherapeutics; 2022 Apr; 19(3):848-863. PubMed ID: 35043373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Paraneoplastic Syndromes in the Era of Immune Checkpoint Inhibitors.
    Jean MJ; Samkoff L; Mohile N
    Curr Treat Options Oncol; 2024 Jan; 25(1):42-65. PubMed ID: 38198120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paraneoplastic neurological syndromes and onconeural antibodies: clinical and immunological aspects.
    Storstein A; Vedeler CA
    Adv Clin Chem; 2007; 44():143-85. PubMed ID: 17682342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paraneoplastic Neurologic Disorders.
    Gilligan M; McGuigan C; McKeon A
    Curr Neurol Neurosci Rep; 2023 Mar; 23(3):67-82. PubMed ID: 36781586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paraneoplastic neurological syndromes.
    Leypoldt F; Wandinger KP
    Clin Exp Immunol; 2014 Mar; 175(3):336-48. PubMed ID: 23937626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors.
    Graus F; Dalmau J
    Nat Rev Clin Oncol; 2019 Sep; 16(9):535-548. PubMed ID: 30867573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
    Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
    J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paraneoplastic neurological syndrome: growing spectrum and relevance.
    Ganaraja VH; Rezk M; Dubey D
    Neurol Sci; 2022 Jun; 43(6):3583-3594. PubMed ID: 35460452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.